Texas Capital Securities analyst Nate Pendleton reiterated a Buy rating and $138.00 price target on Oklo (NYSE: OKLO)

The analyst commented, "Before the open, Oklo announced two regulatory milestones. First, the company announced an Other Transaction Agreement (OTA) with the DOE to support the design, construction, and operation of its first reactor, Aurora-INL, under the DOE's Reactor Pilot Program. With the OTA and NSDA approved, Oklo immediately requested the DOE to commence review of its Preliminary Documented Safety Analysis. Separately, Oklo’s Atomic Alchemy subsidiary received an NRC license for isotope material. This license enables Atomic Alchemy to handle, process, and begin commercial sales from its Idaho Radiochemistry Laboratory. Atomic Alchemy expects to create a valuable feedstock to support medical isotope production, including targeted alpha therapy supply chains. The license helps de-risk Oklo’s isotope sales business and creates a more resilient domestic isotope supply chain. Taken together, we view the announcements as important milestones on the company’s path to building Aurora-INL and establishing a synergistic radioisotope business."

For an analyst ratings summary and ratings history on Oklo click here. For more ratings news on Oklo click here.

Shares of Oklo closed at $59.69 yesterday.